DD297332A5 - Neue orale arzneizubereitung zur verbesserung der verfuegbarkeit - Google Patents
Neue orale arzneizubereitung zur verbesserung der verfuegbarkeit Download PDFInfo
- Publication number
- DD297332A5 DD297332A5 DD90343250A DD34325090A DD297332A5 DD 297332 A5 DD297332 A5 DD 297332A5 DD 90343250 A DD90343250 A DD 90343250A DD 34325090 A DD34325090 A DD 34325090A DD 297332 A5 DD297332 A5 DD 297332A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- pharmaceutical composition
- composition according
- prosobel
- oxodipine
- natural proteins
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 8
- 229940126701 oral medication Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- MSOAVHHAZCMHDI-UHFFFAOYSA-N oxodipine Chemical group CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC2=C1OCO2 MSOAVHHAZCMHDI-UHFFFAOYSA-N 0.000 claims description 26
- 229950009982 oxodipine Drugs 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229960001597 nifedipine Drugs 0.000 claims description 8
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 8
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000006104 solid solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid glycine ester Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8910605A FR2650502B1 (fr) | 1989-08-07 | 1989-08-07 | Nouvelle forme galenique orale ameliorant la biodisponibilite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD297332A5 true DD297332A5 (de) | 1992-01-09 |
Family
ID=9384532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90343250A DD297332A5 (de) | 1989-08-07 | 1990-08-06 | Neue orale arzneizubereitung zur verbesserung der verfuegbarkeit |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0412877A1 (enExample) |
| JP (1) | JPH0377819A (enExample) |
| KR (1) | KR910004181A (enExample) |
| CN (1) | CN1049455A (enExample) |
| AU (1) | AU631235B2 (enExample) |
| CA (1) | CA2022447A1 (enExample) |
| CS (1) | CS383890A3 (enExample) |
| DD (1) | DD297332A5 (enExample) |
| DE (1) | DE4023136A1 (enExample) |
| FI (1) | FI903885A7 (enExample) |
| FR (1) | FR2650502B1 (enExample) |
| GB (1) | GB2234898A (enExample) |
| HU (1) | HU204997B (enExample) |
| IE (1) | IE902629A1 (enExample) |
| IL (1) | IL95105A0 (enExample) |
| IN (1) | IN170789B (enExample) |
| LU (1) | LU87777A1 (enExample) |
| MA (1) | MA21923A1 (enExample) |
| NO (1) | NO903442L (enExample) |
| NZ (1) | NZ234593A (enExample) |
| OA (1) | OA09301A (enExample) |
| PE (1) | PE491A1 (enExample) |
| PT (1) | PT94823A (enExample) |
| TN (1) | TNSN90111A1 (enExample) |
| ZA (1) | ZA905886B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2133633T3 (es) * | 1992-01-17 | 1999-09-16 | Alfatec Pharma Gmbh | Procedimiento para la produccion de polvos, granulados o peletes que contienen una sustancia activa, con una estructura a base de macromoleculas hidrofilas, y su utilizacion. |
| DE4221880A1 (de) * | 1992-07-03 | 1994-01-05 | Alfatec Pharma Gmbh | Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen |
| KR20030089147A (ko) * | 2002-05-16 | 2003-11-21 | 슈라펫 주식회사 | 애완동물용 급수통 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE854414C (de) * | 1949-04-26 | 1952-11-04 | Dieter Dr Med Ellenbeck | Verfahren zur Herstellung von injizierbaren Loesungen von an sich mehr oder weniger schwer loeslichen Arzneimitteln |
| GB715874A (en) * | 1952-10-03 | 1954-09-22 | Horlicks Ltd | A tablet for use in treating peptic ulcers |
| GB906422A (en) * | 1958-05-02 | 1962-09-19 | Wellcome Found | Improvements in and relating to prolonged acting pharmaceutical preparations |
| US3015611A (en) * | 1959-08-25 | 1962-01-02 | Nysco Lab Inc | Low density whey-bound tablets |
| GB1063872A (en) * | 1962-08-11 | 1967-03-30 | Wellcome Found | Improvements in and relating to prolonged acting pharmaceutical compositions |
| US3594467A (en) * | 1968-10-09 | 1971-07-20 | Richardson Merrell Inc | Long-lasting troche |
| US3922379A (en) * | 1973-12-17 | 1975-11-25 | Abbott Lab | Microencapsulation process |
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| DE3250023T (enExample) * | 1981-01-14 | 1990-03-29 | ||
| FR2524312B1 (fr) * | 1982-04-01 | 1985-10-04 | Tech Cuir Centre | Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif |
| JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| CA1249968A (en) * | 1984-04-05 | 1989-02-14 | Kazuo Kigasawa | Ointment base |
| US4670251A (en) * | 1984-05-30 | 1987-06-02 | Igene Biotechnology, Inc. | Microcrystalline tableting excipient derived from whey |
| NZ217844A (en) * | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
| IL78017A (en) * | 1986-03-03 | 1989-06-30 | Yissum Res Dev Co | Sustained release tablets of theophylline |
| DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| EP0326618A1 (en) * | 1987-03-04 | 1989-08-09 | Nippon Hypox Laboratories Incorporated | Medicinal composition containing albumin as carrier and process for its preparation |
| CA1324083C (en) * | 1987-03-09 | 1993-11-09 | Tetsu Miyoshi | Pharmaceutical preparations containing non-steroidal anti-inflammatory agents |
| DK179687D0 (da) * | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
| ATE90205T1 (de) * | 1987-09-08 | 1993-06-15 | Takeda Chemical Industries Ltd | Wasserunloesliche cytokine. |
-
1989
- 1989-08-07 FR FR8910605A patent/FR2650502B1/fr not_active Expired - Fee Related
-
1990
- 1990-07-17 IL IL95105A patent/IL95105A0/xx unknown
- 1990-07-18 IE IE262990A patent/IE902629A1/en unknown
- 1990-07-19 IN IN578/MAS/90A patent/IN170789B/en unknown
- 1990-07-20 DE DE4023136A patent/DE4023136A1/de not_active Withdrawn
- 1990-07-20 NZ NZ234593A patent/NZ234593A/en unknown
- 1990-07-26 PT PT94823A patent/PT94823A/pt not_active Application Discontinuation
- 1990-07-26 ZA ZA905886A patent/ZA905886B/xx unknown
- 1990-08-01 EP EP90402199A patent/EP0412877A1/fr not_active Withdrawn
- 1990-08-01 CA CA002022447A patent/CA2022447A1/fr not_active Abandoned
- 1990-08-01 LU LU87777A patent/LU87777A1/fr unknown
- 1990-08-02 MA MA22193A patent/MA21923A1/fr unknown
- 1990-08-03 GB GB9017144A patent/GB2234898A/en not_active Withdrawn
- 1990-08-03 CS CS903838A patent/CS383890A3/cs unknown
- 1990-08-03 PE PE1990173269A patent/PE491A1/es unknown
- 1990-08-04 KR KR1019900011979A patent/KR910004181A/ko not_active Withdrawn
- 1990-08-06 FI FI903885A patent/FI903885A7/fi not_active Application Discontinuation
- 1990-08-06 HU HU904909A patent/HU204997B/hu not_active IP Right Cessation
- 1990-08-06 DD DD90343250A patent/DD297332A5/de not_active IP Right Cessation
- 1990-08-06 CN CN90106874A patent/CN1049455A/zh active Pending
- 1990-08-06 NO NO90903442A patent/NO903442L/no unknown
- 1990-08-06 AU AU60239/90A patent/AU631235B2/en not_active Ceased
- 1990-08-06 OA OA59830A patent/OA09301A/xx unknown
- 1990-08-06 JP JP2209061A patent/JPH0377819A/ja active Pending
- 1990-08-07 TN TNTNSN90111A patent/TNSN90111A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU204997B (en) | 1992-03-30 |
| NZ234593A (en) | 1993-04-28 |
| CA2022447A1 (fr) | 1991-02-08 |
| FI903885A0 (fi) | 1990-08-06 |
| HUT55230A (en) | 1991-05-28 |
| KR910004181A (ko) | 1991-03-28 |
| IL95105A0 (en) | 1991-06-10 |
| FR2650502A1 (fr) | 1991-02-08 |
| FI903885A7 (fi) | 1991-02-08 |
| TNSN90111A1 (fr) | 1991-03-05 |
| NO903442L (no) | 1991-02-08 |
| DE4023136A1 (de) | 1991-02-14 |
| CS276556B6 (en) | 1992-06-17 |
| GB2234898A (en) | 1991-02-20 |
| FR2650502B1 (fr) | 1994-05-27 |
| IE902629A1 (en) | 1991-02-27 |
| LU87777A1 (fr) | 1990-12-11 |
| HU904909D0 (en) | 1991-01-28 |
| JPH0377819A (ja) | 1991-04-03 |
| ZA905886B (en) | 1991-04-24 |
| CS383890A3 (en) | 1992-06-17 |
| IN170789B (enExample) | 1992-05-23 |
| NO903442D0 (no) | 1990-08-06 |
| PE491A1 (es) | 1991-01-26 |
| GB9017144D0 (en) | 1990-09-19 |
| MA21923A1 (fr) | 1991-04-01 |
| CN1049455A (zh) | 1991-02-27 |
| OA09301A (fr) | 1992-09-15 |
| AU6023990A (en) | 1991-02-07 |
| PT94823A (pt) | 1991-04-18 |
| AU631235B2 (en) | 1992-11-19 |
| EP0412877A1 (fr) | 1991-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1059920B1 (de) | Verwendung von alkylhydrogenfumaraten zur behandlung von psoriasis, psoriatischer arthritis, neurodermitis und enteritis regionalis crohn | |
| DE68904459T2 (de) | Antacidzusammensetzungen mit laengerer verweilzeit im magen. | |
| EP0068191B2 (de) | Orale Dipyridamolformen | |
| EP0108898B1 (de) | Neue orale Mopidamolformen | |
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| DE19541128C2 (de) | Stabilisierte schilddrüsenhormonhaltige Arzneimittel | |
| DE3610531C2 (de) | Arzneimittel mit einem Gehalt an N-(4-Hydroxyphenyl)-retinamid mit erhöhter Bioverfügbarkeit | |
| DE2530563A1 (de) | Arzneimittelformulierungen mit geringem missbrauchpotential | |
| DE29825080U1 (de) | Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit | |
| CH639845A5 (en) | Solid depot pharmaceutical preparations and process for their production | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE69521924T2 (de) | Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE3882157T2 (de) | Nichtsteroide Antientzündungswirkstoffe enthaltende pharmazeutische Zubereitungen. | |
| DE69619052T2 (de) | Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung | |
| DE69128760T2 (de) | Antidiarrhoeika | |
| EP0722719B1 (de) | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen | |
| DE4342568A1 (de) | Coffeinhaltige Kaugummiware | |
| DE69103624T2 (de) | Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung. | |
| DE69100954T2 (de) | Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung. | |
| EP1021198B1 (de) | Flavonolignan-zubereitungen, insbesondere silymarin-zubereitungen | |
| DE3417576A1 (de) | Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung | |
| EP1001756A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE3040042A1 (de) | Pharmazeutische zubereitung des tiaramids oder seiner pharmazeutisch vertraeglichen salze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |